Oxcia’s mission is to revolutionize treatments in cancer and inflammation by targeting DDR, with the goal of saving and improving lives globally. We can’t do this on our own, why we are keen to establish collaborations and/or license agreements with partners from the pharmaceutical/biotech industry and academic research groups in different areas.

Combination with other therapeutics with complementary mechanisms of action is one area of particular interest.

We want to create mutually beneficial partnerships with the end goals of disrupting science and providing significantly better treatments for patients.

We would be very happy to hear from you.

You can contact:

  • Ulrika Warpman Berglund, CEO,
  • Monika Vedin, Business strategy & Communication Director,
  • Jan Zetterberg, Chairman of the Board,